Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy

New England Journal of Medicine 2026

View at publisher
Authors: Joseph W. Rossano, Charles Canter, Cordula M. Wolf, Andrew L. Papez, Marta Gambra, Randall M. Bryant, Juan Alejos, Michael A. McCulloch, Georgia Sarquella‐Brugada, M.J. Bock, Aamir Jeewa, F. Bennett Pearce
+8 more Milind Y. Desai, Nicholas Favatella, Atefeh Javidialsaadi, Van Phung, Thomas A. Rano, Lin Zhu, Joshua L. Dyme, Seema Mital
DOI: 10.1056/nejmoa2601103
Cited by: 7
References: 38

Abstract

BACKGROUND: Approved pharmacologic therapies for pediatric hypertrophic cardiomyopathy are lacking, and surgical intervention may be indicated in patients with left ventricular outflow tract obstruction. The efficacy and safety of mavacamten, a cardiac myosin inhibitor that is available for adults, warrant evaluation in adolescents. METHODS: We conducted a phase 3, double-blind, randomized, placebo-controlled trial involving symptomatic adolescents (12 to

Fields of Study & Subjects

Cardiomyopathy and Myosin Studies Cardiovascular Effects of Exercise Pericarditis and Cardiac Tamponade

Publication details

Journal / source
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Volume
395
Issue
4
Pages
362–373
Publication date
29 March 2026
Language
EN